OncoZenge Q1: Pieces falling into place - Redeye

Redeye provides a research update following the Q1 report published by OncoZenge earlier today. The company manages to maintain a low OPEX and cash burn as the prepares for the upcoming phase III trial. Bolstered by a binding partnership agreement with Molteni, an NDRC approval of the financing agreement with Yangtian Pharma and a new licensing agreement with Avernus Pharma, we argue that the pieces are falling into place for the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/1109186/oncozenge-q1-pieces-falling-into-place?utm_source=finwire&utm_medium=RSS